Novacyt SA
PAR:ALNOV
Novacyt SA
PAR:ALNOV
Price:
0.3725
EUR
-1.84%
Market Closed
Market Cap:
€27m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Novacyt SA
PAR:ALNOV
|
FR |
|
B
|
Bank Of Princeton
NASDAQ:BPRN
|
US |
Multiples-Based Value
The Multiples-Based Value of one
ALNOV
stock under the Base Case scenario is
0.8346
EUR.
Compared to the current market price of 0.3725 EUR,
Novacyt SA
is
Undervalued by 55%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ALNOV
Multiples-Based Value
Base Case
0.8346
EUR
Undervaluation 55%
Multiples Across Competitors
ALNOV Competitors Multiples
Novacyt SA Competitors
Novacyt SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
|
Novacyt SA
PAR:ALNOV
|
26.3m EUR | 1.2 | -0.8 | -0.7 | -0.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.4B USD | 6 | 87.3 | 14.5 | 20.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.6B USD | 5 | 23.9 | 13.9 | 13.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.9B USD | 5.9 | 20.5 | 12.8 | 15.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.3B USD | 9.2 | 27.9 | 20.9 | 21.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.7B USD | 5.6 | 17.9 | 13.4 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD | 3.1 | 34.4 | 11.4 | 14.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.2 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
